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where adequate expertise and resources are available without in-
curring delay.” Our further recommendations for future work, that
a large multicenter randomized controlled trial be performed and
that centers performing endovascular repair of ruptured aneurysms
contribute to a central registry, are also unchanged.
Tara M. Mastracci, MD
Luis Garrido-Olivares, MD
Claudio S. Cina, MD, Spec Chir(lt), FRCS(c), MSc, a
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Regarding “Informed consent for AAA repair:
Assessing variations in surgeon opinion through a
national survey”
Berman et al1 are to be commended for seeking “to define
national surgeon opinion regarding the content of informed con-
sent discussions” for AAA repair, but leave out an important
aspect. Although they cite the two randomized trials demonstrat-
ing no benefit from repair of AAA smaller than 5.5 cm in diameter
and note that the legal definition of informed consent “includes
discussion of the risks, benefits, and alternatives to an interven-
tion”, they neglect to ask in their survey whether the surgeon
discussed the trial results with patients who have AAA smaller than
5.5 cm. If patients with AAA substantially below this threshold are
told that they “need” AAA repair and subsequently suffer an
adverse outcome, preoperative review of the surgical risks without
discussion of whether repair was indicated may not be considered
sufficient.
Frank A. Lederle, MD
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We agree that discussion of whether repair is indicated is an
essential component of informed consent not only for patients
with smaller aneurysms but for all patients considering AAA repair.
This falls under the category of discussion of “alternatives to
intervention”, the alternative in this case being no intervention at
all. In our survey, 97% of respondents stated that it was essential to
discuss outcomes related to nonintervention during informed con-
sent. (We did not discuss these findings due to space limitations.)
We did not ask specifically about informed consent practices with
patients with aneurysms 5.5 cm, but we believe that it is impor-
tant in all cases to present the data and help each individual patient
arrive at the treatment decision that is best for them rather than
telling anyone that they “need” an aneurysm repair.
Loren Berman, MD
Alan Dardik, MD, PhD
Richard Gusberg, MD
Liana Fraenkel, MD, MPH
Yale University School of Medicine
New Haven, Conn
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Regarding “Endovascular vs open repair of acute
abdominal aortic aneurysms–A systematic review and
meta-analysis”
The recent meta-analysis comparing endovascular with open
repair of acute (ruptured or symptomatic intact) abdominal aortic
aneurysms (AAAs) supports a considerable benefit of endovascular
aneurysm repair (EVAR) procedures.1 Compared with open re-
pair, EVAR was associated with a significant 38% reduction in
mortality (pooled odds ratio, 0.624; 95% confidence interval [CI],
0.518 to 0.752; P  .0001), a shorter intensive care unit (pooled
effect size estimate, 0.70 days; 95% CI, 1.05 to 0.35 days;
P  .0001), and hospital stay (pooled effect size estimate, 0.33
days; 95% CI, 0.50 to 0.16 days; P  .0001), as well as a
significant reduction in blood loss (pooled effect size estimate,
1.88 lt; 95% CI, 2.49 to 1.27 lt; P  .0001) and procedure
time (pooled effect size estimate, 0.65 hours; 95% CI, 0.95 to
0.36 hours; P  .0001).1
In two of the five parameters examined in the meta-analysis,
there was evidence of both heterogeneity and bias, that is, in
intensive care unit stay (heterogeneity: Cochran Q test, 46.57; P
.0001; bias: Egger test, 3.98; P  .0085), and operative blood
loss (heterogeneity: Cochran Q test, 51.91; P .0001; bias: Egger
test, 4.94; P  .0032).1 In another two parameters, there was
evidence of either heterogeneity or bias, ie, in mortality (hetero-
geneity: Cochran Q test, 15.449; P  .750; bias: Egger test,
0.649; P .017) and procedure duration (heterogeneity: Coch-
ran Q test, 30.82; P  .0012; bias: Egger test, 0.34; P  .82).1
The only parameter showing neither significant heterogeneity nor
bias was the length of postoperative stay.1
Additionally, in all the trials evaluated in the meta-analysis, the
inclusion criteria for study entry were: (1) adequate hemodynamic
stability for patients to undergo a preoperative CT scan, (2) AAA
anatomical suitability for EVAR (eg, appropriate proximal neck
length), and/or (3) the presence of sufficient personnel for the
performance of EVAR. When these inclusion criteria were not met,
the patient was either excluded from the study or an emergency
open AAA repair was performed.
Another drawback that questions the validity of the results of
this meta-analysis is that only one of the 23 studies included was a
randomized controlled trial between EVAR and open repair for
ruptured AAAs;2 however, this study also had several exclusion
criteria.2
Based on the specificity of the selection/inclusion criteria, as
well as the reported heterogeneity and associated bias of the
reported results, it may be premature for any definite conclusions
to be drawn. EVAR may be a reasonable option for symptomatic
(but intact) AAAs; however, in true emergency AAAs (as in the case
of ruptured AAAs), patients may not be hemodynamically stable
for a preoperative evaluation CT scan of the AAA anatomy to be
performed. There may also be ethical limitations in designing
appropriate randomized controlled trials to provide definitive
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answers. Consequently, EVAR may be an option for symptomatic
intact, but not for ruptured AAAs.
Kosmas I. Paraskevas, MD, FASA
Department of Vascular Surgery
“Red Cross” Hospital
Athens, Greece
Honorary Clinical Research Fellow
Department of Clinical Biochemistry (Vascular Disease
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The issues surrounding the role of endovascular aneurysm
repair (EVAR) in the management of ruptured abdominal aortic
aneurysms (AAAs) are complex. This meta-analysis set out to
examine the current published data. Statistical analysis of the
overall hospital length of stay was not affected by heterogeneity or
bias and showed an 8.6-day reduction in those patients treated
with EVAR relative to open surgery. We suspect that most sur-
geons, patients, and hospital managers would be very pleased with
this outcome.
Although we accept that there may be some potential publi-
cation bias that resulted in us finding a 37.6% reduction in mortal-
ity and a 4-day reduction in the intensive treatment unit with
EVAR, these findings would be supported by the overall improve-
ment in length of stay. It is very difficult to see how these data
could be interpreted in such a negative way for the authors of the
letter to state “EVAR may be an option for symptomatic intact, but
not for ruptured AAAs.”
Many people have called for more randomized controlled
trials in this area, and some have even tried to run them. We believe
that trying to find out whether open repair or EVAR is better for
ruptured AAAs is asking the wrong question. A trial such as this
would exclude two important groups—those not stable enough
for EVAR and those who are not potentially fit enough to survive
an open repair. Those in the latter group are not EVAR II type
patients because they have ruptured AAAs and their immediate life
expectancy is very different. The question that should be asked
about EVAR is “What happens to the overall mortality of all
patients admitted to our institution with ruptured AAAs if we
include EVAR in our armamentarium?”
Centers committed to offering the best treatment for patients
with ruptured AAAs should provide a service that can offer EVAR
on a 24-hour basis.
Umar Sadat, MB BS, MRCS
Paul Hayes, MD, FRCS
Clinical Research Associate, Vascular Imaging
Addenbrooke’s Hospital
Cambridge University Hospitals NHS Foundation Trust
Cambridge, United Kingdom
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Carotid endarterectomy under local anesthesia may be
the treatment of choice for symptomatic carotid
artery stenosis
Two recent meta-analyses comparing carotid endarterectomy
(CEA) with carotid artery stenting (CAS) for symptomatic carotid
artery stenosis showed that CEA is superior to CAS with respect to
30-day stroke/death rates.1,2 The first meta-analysis included
2985 patients of whom 2646 (89%) were symptomatic and showed
a significant 38% increase in the odds of any stroke or death 30
days after treatment (odds ratio, 1.38; 95% confidence interval
[CI], 1.04-1.83; P  .024).1 The second meta-analysis included
3580 patients and showed that although patients undergoing CAS
had a higher risk of 30 day-stroke/death compared with patients
undergoing CEA (risk ratio [RR], 1.30; 95% CI, 1.01-1.67; P 
.05), the 30-day risk of stroke was not significantly different
between patients who underwent CAS vs CEA (RR, 1.27; 95% CI,
0.96-1.69).2 However, a subgroup analysis of trials enrolling only
symptomatic patients showed a higher risk of both 30-day stroke/
death (RR, 1.63; 95% CI, 1.18-2.25; P  .05) and 30-day stroke
rates (RR, 1.62; 95% CI, 1.13-2.31; P  .05) in CAS patients.2
The conclusion reached was that “surgical treatment still remains
the gold standard for treatment of patients with symptomatic
carotid artery stenosis, who do not have an increased risk.”1
In most of the trials included in the two meta-analyses, CEA
was performed under general anesthesia.1,2 A parameter that may
produce even better results for CEA compared with CAS (eg, even
lower 30-day stroke rates) is the performance of CEA under local
instead of general anesthesia. The use of local anesthesia for CEA
gives the surgeon the opportunity to directly assess the neurologic
status of the patient during the procedure. Moreover, CEA can be
safely performed under local anesthesia, even in high-risk patients.
A retrospective study of 365 procedures showed that the
performance of 200 CEAs with local anesthesia compared with
165 under general anesthesia was associated with significantly
lower stroke rates (1% vs 7.3%, respectively; P  .05), operation
time (104.5  24 vs 122  36 minutes, respectively; P  .0001),
cross-clamping time (14.6  4 vs 18.2  5 minutes, respectively;
P  .0001) and intraoperative shunt usage (8% vs 30.3%, respec-
tively; P  .0001).3 In addition, application of local instead of
general anesthesia was associated with decreased length of hospi-
talization (2.4  1.1 vs 4.1  1.9 days, respectively; P  .0001)
and associated costs ($885.71 $78.57 vs $1007.14 $135.71,
respectively; P  .0001).3 The superiority of local compared with
general anesthesia for CEA was supported in other similar trials, as
well.4,5
A drawback of these studies3-5 is their retrospective nature. A
prospective, multicenter randomized study, the General Anaes-
thetic versus Local Anaesthetic for carotid surgery (GALA) trial,
will soon report its results from 3529 patients undergoing CEA
under local vs general anesthesia.6 In the future, a similar, prospec-
tive, multicenter randomized trial comparing CAS with CEA per-
formed under local anesthesia may lead to the conclusion that “the
gold standard for symptomatic carotid artery stenosis” is indeed
surgical treatment, performed however, under local anesthesia.
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